<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956953</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-053</org_study_id>
    <nct_id>NCT03956953</nct_id>
  </id_info>
  <brief_title>Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single- And Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-986165 in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective of this study is to assess BMS-986165 plasma PK following single and multiple
      oral doses of BMS-986165 in healthy Chinese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Actual">September 25, 2019</completion_date>
  <primary_completion_date type="Actual">September 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There will be two dose groups. Once the safety and tolerability up to discharge (Day 24) of Group 1, has been assessed and deemed safe; dosing for Group 2 will begin.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of BMS-986165</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of BMS-986165</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under The Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) of BMS-986165</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under The Plasma Concentration-Time Curve From Time Zero Extrapolated To Infinite Time (AUC(INF)) of BMS-986165</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Plasma Elimination Half-Life (T-HALF) of BMS-986165</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Total Body Clearance (CLT/F) of BMS-986165</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Ratio for AUC(INF) of Metabolite (BMT-153261 and BMT-158170) Over Parent (BMS-986165) - MR(AUC[INF])</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Ratio for Cmax of Metabolite (BMT-153261 and BMT-158170) Over Parent (BMS-986165) - MR(Cmax)</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of BMS-986165</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of BMS-986165</measure>
    <time_frame>Day 5 to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve in a Dosing Interval (AUC(TAU)) of BMS-986165</measure>
    <time_frame>Day 5 and Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effective Elimination Half-Life (T-HALFeff) of BMS-986165</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Observed Plasma Concentration (Ctrough) of BMS-986165</measure>
    <time_frame>Day 2 to 20</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Plasma Concentration at Steady State (Css-avg) of BMS-986165</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Index (AI) of BMS-986165</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic Ratio for AUC(TAU) of Metabolite (BMT-153261 and BMT-158170) Over Parent (BMS-986165) - MR(AUC[TAU])</measure>
    <time_frame>Day 5 to Day 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of Fluctuation (DF) of BMS-986165</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AEs)</measure>
    <time_frame>Up to Day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Clinical Laboratory Values</measure>
    <time_frame>Up to Day 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Vital Signs</measure>
    <time_frame>Up to Day 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG)</measure>
    <time_frame>Up to Day 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Physical Examination</measure>
    <time_frame>Up to Day 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Metabolites BMT-153261 and BMT-158170</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of B Metabolites BMT-153261 and BMT-158170</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) of Metabolites BMT-153261 and BMT-158170</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Plasma Concentration-Time Curve From Time Zero Extrapolated To Infinite Time (AUC(INF)) of Metabolites BMT-153261 and BMT-158170</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Plasma Elimination Half-Life (T-HALF) of Metabolites BMT-153261 and BMT-158170</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve in a Dosing Interval (AUC(TAU)) of Metabolites BMT-153261 and BMT-158170</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective Elimination Half-Life (T-HALFeff) of Metabolites BMT-153261 and BMT-158170</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Observed Plasma Concentration (Ctrough) of Metabolites BMT-153261 and BMT-158170</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Plasma Concentration at Steady State (Css-avg) of Metabolites BMT-153261 and BMT-158170</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index (AI) of Metabolites BMT-153261 and BMT-158170</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Fluctuation (DF) of Metabolites BMT-153261 and BMT-158170</measure>
    <time_frame>Days 1 to 4, Day 5, and Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Drug Recovered in Urine (URt) Following Single Oral Doses of BMS-986165</measure>
    <time_frame>Day 1 to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Percent of Administered Dose Recovered Unchanged in Urine (%URt) Following Single Oral Doses of BMS-986165</measure>
    <time_frame>Day 1 to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CLR) Following Single Oral Doses of BMS-986165</measure>
    <time_frame>Day 1 to Day 5</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Group 1: BMS-986165 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Dose 1 on Day 1, and from Day 5 - 19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: BMS-986165 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Dose 2 on Day 1, and from Day 5 - 19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Placebo Dose 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching Dose 1 on Day 1, and from Day 5 - 19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Placebo Dose 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching Dose 2 on Day 1, and from Day 5 - 19.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <description>Dose 1 or Dose 2 on Day 1, and from Days 5-19'</description>
    <arm_group_label>Group 1: BMS-986165 Dose 1</arm_group_label>
    <arm_group_label>Group 2: BMS-986165 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19</description>
    <arm_group_label>Group 1: Placebo Dose 1</arm_group_label>
    <arm_group_label>Group 2: Placebo Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent.

          -  Healthy participants, as determined by physical examination, ECGs, and clinical
             laboratory and procedure determinations.

          -  Body mass index (BMI) of 18 to 24 kg/m2, inclusive, and total body weight &gt;= 50 kg.

        Exclusion Criteria:

          -  History of allergy to drug class or related compounds.

          -  History or evidence of active infection within 7 days of study day 1.

          -  Drug or alcohol abuse within 6 months of study treatment administration.

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BMS-986165</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

